Takeda Pharmaceutical Company (TAK) Gets a Buy from Bank of America Securities
TipRanks (Mon, 14-Sep 11:35 AM ET)
Business Wire (Mon, 14-Sep 3:00 AM ET)
Takeda’s OBIZUR Surveillance Study: Real World Data That Could Steady TAK’s Growth
TipRanks (Fri, 11-Sep 12:31 PM ET)
Takeda Advances Pediatric Bleeding Disorder Program With New Vonicog Alfa Study Update
TipRanks (Wed, 9-Sep 12:31 PM ET)
Business Wire (Wed, 9-Sep 8:24 AM ET)
Business Wire (Fri, 28-Aug 6:40 PM ET)
Business Wire (Mon, 24-Aug 2:36 AM ET)
Takeda’s FDA Approval for ORZEYFUL Sets a New Standard in Narcolepsy Type 1 Care
Market Chameleon (Thu, 6-Aug 5:13 AM ET)
Business Wire (Wed, 5-Aug 6:10 PM ET)
Business Wire (Thu, 30-Jul 2:37 AM ET)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of Common Stock) trades on the NYSE stock market under the symbol TAK.
As of September 14, 2026, TAK stock price climbed to $18.60 with 2,250,001 million shares trading.
TAK has a beta of 0.16, meaning it tends to be less sensitive to market movements. TAK has a correlation of 0.01 to the broad based SPY ETF.
TAK has a market cap of $59.40 billion. This is considered a Large Cap stock.
Last quarter Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of Common Stock) reported $8 billion in Revenue and $.48 earnings per share. This beat revenue expectation by $595 million and exceeded earnings estimates by $.09.
In the last 3 years, TAK traded as high as $18.90 and as low as $12.58.
The top ETF exchange traded funds that TAK belongs to (by Net Assets): FVD, PPH, AVDE, APIE, VEU.
TAK has outperformed the market in the last year with a price return of +21.3% while the SPY ETF gained +16.8%. TAK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.2% and +3.2%, respectively, while the SPY returned +3.4% and -1.1%, respectively.
TAK support price is $18.03 and resistance is $18.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TAK shares will trade within this expected range on the day.